LifeStance Health Group (NASDAQ:LFST) Upgraded to “Strong-Buy” at Wall Street Zen

Posted by George Bondi on Aug 16th, 2026

Wall Street Zen upgraded shares of LifeStance Health Group (NASDAQ:LFST – Free Report) from a buy rating to a strong-buy rating in a report issued on Saturday morning.

LFST has been the topic of a number of other research reports. Weiss Ratings raised shares of LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday. The Goldman Sachs Group initiated coverage on shares of LifeStance Health Group in a research report on Friday, June 5th. They set a “neutral” rating and a $9.00 price target for the company. Barclays boosted their price target on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. KeyCorp increased their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. lifted their target price on shares of LifeStance Health Group from $9.00 to $13.00 and gave the company a “neutral” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.12.

Read Our Latest Stock Analysis on LFST

LifeStance Health Group Trading Up 1.6%

Shares of LifeStance Health Group stock opened at $12.42 on Friday. The firm has a market capitalization of $4.82 billion, a price-to-earnings ratio of 95.55 and a beta of 1.14. LifeStance Health Group has a fifty-two week low of $4.77 and a fifty-two week high of $12.76. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The stock has a 50 day moving average of $10.39 and a 200 day moving average of $8.22.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The company had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.01) earnings per share. As a group, research analysts predict that LifeStance Health Group will post 0.15 earnings per share for the current year.

Insider Buying and Selling at LifeStance Health Group

In other LifeStance Health Group news, Director Robert Bessler sold 894,337 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $10.13, for a total transaction of $9,059,633.81. Following the sale, the director directly owned 539,763 shares in the company, valued at $5,467,799.19. This represents a 62.36% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Lisa K. Miller sold 47,912 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $10.85, for a total transaction of $519,845.20. Following the sale, the chief operating officer owned 281,289 shares in the company, valued at approximately $3,051,985.65. This trade represents a 14.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 14,629,850 shares of company stock worth $154,952,012. 3.50% of the stock is owned by company insiders.

Institutional Trading of LifeStance Health Group

A number of large investors have recently modified their holdings of LFST. BlackRock Inc. purchased a new position in LifeStance Health Group in the second quarter valued at $389,293,000. Silversmith Partners I GP LLC acquired a new stake in LifeStance Health Group in the 4th quarter valued at about $100,842,000. Vanguard Group Inc. raised its position in LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after purchasing an additional 3,086,506 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after buying an additional 2,843,388 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after buying an additional 1,839,465 shares during the period. Hedge funds and other institutional investors own 85.50% of the company’s stock.

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.